In vitro assessment of 2-acetylpyridine thiosemicarbazones against chloroquine-resistant Plasmodium falciparum. 1982

C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson

A series of 2-acylpyridine thiosemicarbazones was evaluated in vitro against a chloroquine-resistant Plasmodium falciparum strain. Antimalarial activity was assessed by the inhibition of uptake of [G-3H]hypoxanthine by the parasites. Among the mono- and disubstituted derivatives tested, 13 of 17 had 50% inhibitory doses of less than 10 ng/ml. Increasing the size of the ring at N4 from four to five, six, and seven members produced concomitant decreases in activity. Similarly, increasing the size of the aliphatic substituent on the azomethine carbon reduced activity. Selected compounds were also tested against a chloroquine-susceptible strain. The results suggested that the activities of these agents were not modified significantly by resistance to chloroquine. In general, in vitro activities correlate poorly with the in vivo activities in mice infected with Plasmodium berghei.

UI MeSH Term Description Entries
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011739 Pyrimethamine One of the FOLIC ACID ANTAGONISTS that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. Chloridin,Daraprim,Malocide,Tindurine
D011804 Quinolines
D002738 Chloroquine The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. Aralen,Arechine,Arequin,Chingamin,Chlorochin,Chloroquine Sulfate,Chloroquine Sulphate,Khingamin,Nivaquine,Sulfate, Chloroquine,Sulphate, Chloroquine
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013882 Thiosemicarbazones Thiosemicarbazone

Related Publications

C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson
June 1993, Indian journal of malariology,
C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson
May 1981, The American journal of tropical medicine and hygiene,
C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson
January 2001, Journal of postgraduate medicine,
C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson
January 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene,
C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson
December 1984, The Journal of infectious diseases,
C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson
August 1980, Antimicrobial agents and chemotherapy,
C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson
January 1983, Lancet (London, England),
C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson
November 1971, The American journal of tropical medicine and hygiene,
C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson
September 2012, Bioorganic & medicinal chemistry letters,
C Lambros, and G E Childs, and J D Notsch, and J P Scovill, and D L Klayman, and D E Davidson
May 1983, Lancet (London, England),
Copied contents to your clipboard!